Real‐world <i>EGFR</i> testing in patients with stage IIIB/IV non‐small‐cell lung cancer in North China: A multicenter, non‐interventional study
Ying Cheng(Nanjing University), Bing Li(Wuhan University), Zhendong Zheng(General Hospital of Shenyang Military Region), Daxin Zhang(Beijing Forestry University), Kewei Ma(Jilin University), Zhuohui Qu(Zhejiang Cancer Hospital), Hongmei Piao(Yanbian University Hospital), Hongjun Gao(Chinese PLA General Hospital), Yinyin Li(Shenyang 242 Hospital), Xiaoling Li(University of Science and Technology of China), Jie Zhang(Jilin University), Jun Chen(Fourth People's Hospital of Taiyuan), Cheng‐Bo Han, Jun Zhao(Beijing Institute of Technology), Hua Xin(Union Hospital), Shucai Zhang(Northeastern University), Zhitu Zhu(First Affiliated Hospital of Liaoning Medical University), Yuqing Xu(Harbin Medical University), Jiwei Liu(Mongolian University of Science and Technology), Zhaoxia Dai(Dalian Medical University), Fugang Wen(Anshan Hospital), Yongzhi Zhuang(Daqing Oilfield General Hospital), Haibo Yang(Ningxia Medical University), Chunxia Pan(The Third People's Hospital of Dalian City), Min Zhong(Affiliated Hospital of Southwest Medical University), Yunpeng Liu(Shenyang Institute of Automation), Rui Ma(Chinese Academy of Medical Sciences & Peking Union Medical College), Junling Li(Harbin University of Commerce), Yan Wang(National Institute of Biological Sciences, Beijing), Fan Yang(Peking University People's Hospital)
Cited by 37
Related Papers
Food, nutrition, physical activity, and the prevention of cancer: a global perspective
|Choice Reviews Online|2008|5.4k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k